NeuroSense Therapeutics shares positive results of lead candidate in ALS
The neurodegenerative disease currently affects more than 200,000 people worldwide
Read Moreby Jen Brogan | Jul 5, 2024 | News | 0
The neurodegenerative disease currently affects more than 200,000 people worldwide
Read Moreby Jen Brogan | Oct 26, 2023 | News | 0
The two projects will be awarded $1m each to support their clinical investigations
Read Moreby Jen Brogan | Oct 11, 2023 | News | 0
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read Moreby Lucy Parsons | Aug 6, 2021 | News | 0
Acquisition strengthens Bayer’s drug discovery capabilities
Read Moreby Lucy Parsons | Jul 22, 2021 | News | 0
Verquvo cleared for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction
Read Moreby Lucy Parsons | Jul 14, 2021 | News | 0
The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study
Read Moreby Lucy Parsons | Jun 21, 2021 | News | 0
Approval makes Astepro the first and only OTC steroid free antihistamine nasal spray available in the US
Read Moreby Lucy Parsons | Jun 10, 2021 | News | 0
German pharma company announces progress in its ‘two-pronged’ cell and gene therapy approach to Parkinson’s disease
Read Moreby Lucy Parsons | Feb 2, 2021 | News | 0
First oral factor Xa inhibitor approved for paediatric venous thromboembolism
Read Moreby Lucy Parsons | Dec 3, 2020 | News | 0
Platform will enable Bayer to pursue external collaborations and bolster internal capabilities
Read Moreby Lucy Parsons | Dec 2, 2020 | News | 0
Agreement will aim to develop a platform to support radiologists’ decision-making
Read Moreby Lucy Parsons | Oct 27, 2020 | News | 0
Drug authorised for use in non-metastatic castration-resistant prostate cancer
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
